Prolonged SARS-CoV-2 Infection and Organizing Pneumonia in a Patient with Follicular Lymphoma, Treated with Obinutuzumab—Challenging Recognition and Treatment
A Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) led to a pandemic outbreak in 2019. COVID-19’s course and its treatment in immunocompromised patients are uncertain. Furthermore, there is a possibility of protracted SARS-CoV-2 infection and t...
Main Authors: | E. Łyżwa, M. Sobiecka, K. Lewandowska, I. Siemion-Szcześniak, I. Barańska, M. Klatt, R. Langfort, M. Szturmowicz, W. Tomkowski |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-03-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/15/3/693 |
Similar Items
-
Prolonged SARS‐CoV‐2 infection during obinutuzumab and bendamustine treatment for follicular lymphoma: A case report
by: Ryosuke Kambe, et al.
Published: (2023-09-01) -
The clinical development of obinutuzumab for the treatment of follicular lymphoma
by: Ma B, et al.
Published: (2017-04-01) -
The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA)
by: Claudio Jommi, et al.
Published: (2019-11-01) -
Disseminated Enterovirus Infection in a Patient Affected by Follicular Lymphoma Treated with Obinutuzumab: A Case Report and a Narrative Review of the Literature
by: Tommaso Lupia, et al.
Published: (2024-03-01) -
Cost–effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma
by: Jun Ma, et al.
Published: (2023-11-01)